CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
9/12/2012 10:33:47 AM
More...
|
CSL Biotherapies Receives US FDA Warning for GMP Violations at Vaccine Plant
6/28/2011 8:39:34 AM
More...
|
CSL Biotherapies Obtains FDA Licensure for Use of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine in Children
11/12/2009 9:10:48 AM
More...
|
Merck & Co., Inc. (MRK) (JOBS) Obtains Exclusive U.S. Marketing Rights for AFLURIA(R), Seasonal Influenza Vaccine from CSL Biotherapies
9/28/2009 6:20:59 AM
More...
|
CSL Biotherapies Announces Start of U.S. H1N1 Vaccine Clinical Trials
8/24/2009 9:21:18 AM
More...
|
CSL Biotherapies Starts Shipment of Seasonal Influenza Vaccine for the 2009-2010 Flu Season
7/27/2009 8:29:34 AM
More...
|
CSL Biotherapies Contracts with U.S. Department of Health and Human Services to Provide Novel A (H1N1) Influenza Vaccine Antigen
5/29/2009 8:40:50 AM
More...
|
CSL Biotherapies Announces Influenza Vaccine Pre-Booking Open for the 2009-2010 Flu Season
12/18/2008 11:56:10 AM
More...
|
CSL Biotherapies Launches www.mercuryfreefluvaccine.com, An Online, Order-As-You-Go Service for Thimerosal-Free Influenza Vaccine
10/16/2008 11:57:59 AM
More...
|
Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria(R) Published in Vaccine
9/3/2008 9:22:12 AM
More...
|
|